| 臺大學術典藏 |
2021-08-31T06:29:30Z |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
|
Kudo M.; Finn R.S.; Qin S.; Han K.-H.; Ikeda K.; Piscaglia F.; Baron A.; Park J.-W.; Han G.; Jassem J.; Blanc J.F.; Vogel A.; Komov D.; Evans T.R.J.; Lopez C.; Dutcus C.; Guo M.; Saito K.; Kraljevic S.; Tamai T.; Ren M.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:28Z |
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYnote-224): a non-randomised, open-label phase 2 trial
|
Zhu A.X.; Finn R.S.; Edeline J.; Cattan S.; Ogasawara S.; Palmer D.; Verslype C.; Zagonel V.; Fartoux L.; Vogel A.; Sarker D.; Verset G.; Chan S.L.; Knox J.; Daniele B.; Webber A.L.; Ebbinghaus S.W.; Ma J.; Siegel A.B.; ANN-LII CHENG; Kudo M.; Alistar A.; Asselah J.; Blanc J.-F.; Borbath I.; Cannon T.; Chung K.; Cohn A.; Cosgrove D.P.; Damjanov N.; Gupta M.; Karino Y.; Karwal M.; Kaubisch A.; Kelley R.; Van Laethem J.-L.; Larson T.; Lee J.; Li D.; Manhas A.; Manji G.A.; Numata K.; Parsons B.; Paulson A.S.; Pinto C.; Ramirez R.; Ratnam S.; Rizell M.; Rosmorduc O.; Sada Y.; Sasaki Y.; Stal P.I.; Strasser S.; Trojan J.; Vaccaro G.; Van Vlierberghe H.; Weiss A.; Weiss K.-H.; Yamashita T.; KEYnote-224 investigators |
| 臺大學術典藏 |
2021-08-31T06:29:23Z |
Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma
|
Evans T.R.J.; Kudo M.; Finn R.S.; Han K.-H.; ANN-LII CHENG; Ikeda M.; Kraljevic S.; Ren M.; Dutcus C.E.; Piscaglia F.; Sung M.W. |
| 臺大學術典藏 |
2021-08-31T06:29:22Z |
Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma (British Journal of Cancer, (2019), 121, 3, (218-221), 10.1038/s41416-019-0506-6)
|
Evans T.R.J.; Kudo M.; Finn R.S.; Han K.-H.; ANN-LII CHENG; Ikeda M.; Kraljevic S.; Ren M.; Dutcus C.E.; Piscaglia F.; Sung M.W. |
| 臺大學術典藏 |
2021-08-31T06:29:20Z |
Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma
|
Alsina A.; Kudo M.; Vogel A.; ANN-LII CHENG; Tak W.Y.; Ryoo B.-Y.; Evans T.R.J.; L?pez L?pez C.; Daniele B.; Misir S.; Ren M.; Izumi N.; Qin S.; Finn R.S. |
| 臺大學術典藏 |
2021-08-31T06:29:19Z |
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYnote-240: A Randomized, Double-Blind, Phase III Trial
|
Finn R.S.; Ryoo B.-Y.; Merle P.; Kudo M.; Bouattour M.; Lim H.Y.; Breder V.; Edeline J.; Chao Y.; Ogasawara S.; Yau T.; Garrido M.; Chan S.L.; Knox J.; Daniele B.; Ebbinghaus S.W.; Chen E.; Siegel A.B.; Zhu A.X.; ANN-LII CHENG; KEYnote-240 investigators |
| 臺大學術典藏 |
2021-08-31T06:29:19Z |
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
|
ANN-LII CHENG; Hsu C.; Chan S.L.; Choo S.-P.; Kudo M. |
| 臺大學術典藏 |
2021-08-31T06:29:17Z |
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
|
Finn R.S.; Qin S.; Ikeda M.; Galle P.R.; Ducreux M.; Kim T.-Y.; Kudo M.; Breder V.; Merle P.; Kaseb A.O.; Li D.; Verret W.; Xu D.-Z.; Hernandez S.; Liu J.; Huang C.; Mulla S.; Wang Y.; Lim H.Y.; Zhu A.X.; ANN-LII CHENG; IMbrave150 Investigators |
| 臺大學術典藏 |
2021-08-31T06:29:17Z |
IMbrave 050: A Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation
|
Hack S.P.; Spahn J.; Chen M.; ANN-LII CHENG; Kaseb A.; Kudo M.; Lee H.C.; Yopp A.; Chow P.; Qin S. |
| 臺大學術典藏 |
2021-08-31T06:29:17Z |
A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements
|
Kudo M.; Han K.-H.; Ye S.-L.; Zhou J.; Huang Y.-H.; Lin S.-M.; Wang C.-K.; Ikeda M.; Chan S.L.; Choo S.P.; Miyayama S.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:13Z |
Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYnote-240
|
Ryoo B.-Y.; Merle P.; Kulkarni A.S.; ANN-LII CHENG; Bouattour M.; Lim H.Y.; Breder V.; Edeline J.; Chao Y.; Ogasawara S.; Yau T.; Garrido M.; Chan S.L.; Daniele B.; Norquist J.M.; Chen E.; Siegel A.B.; Zhu A.X.; Finn R.S.; Kudo M. |
| 臺大學術典藏 |
2021-07-03T03:34:45Z |
Asian pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma
|
Omata M.; Lesmana L.A.; Tateishi R.; PEI-JER CHEN; Lin S.-M.; Yoshida H.; Kudo M.; Lee J.M.; Choi B.I.; Poon R.T.P.; Shiina S.; Cheng A.L.; Jia J.-D.; Obi S.; Han K.H.; Jafri W.; Chow P.; Lim S.G.; Chawla Y.K.; Budihusodo U.; Gani R.A.; Lesmana C.R.; Putranto T.A.; Liaw Y.F.; Sarin S.K. |
| 臺大學術典藏 |
2021-07-03T03:34:19Z |
Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC)
|
Park J.-W.; Amarapurkar D.; Chao Y.; PEI-JER CHEN; Geschwind J.-F.H.; Goh K.L.; Han K.-H.; Kudo M.; Lee H.C.; Lee R.-C.; Lesmana L.A.; Lim H.Y.; Paik S.W.; Poon R.T.; Tan C.-K.; Tanwandee T.; Teng G.; Cheng A.-L. |
| 臺大學術典藏 |
2021-07-03T03:34:14Z |
Re-evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel
|
Cheng A.L.; Amarapurkar D.; Chao Y.; PEI-JER CHEN; Geschwind J.-F.; Goh K.L.; Han K.-H.; Kudo M.; Lee H.C.; Lee R.-C.; Lesmana L.A.; Lim H.Y.; Paik S.W.; Poon R.T.; Tan C.-K.; Tanwandee T.; Teng G.; Park J.-W. |
| 臺大學術典藏 |
2021-07-03T03:33:58Z |
Global patterns of hepatocellular carcinoma management from diagnosis to death: The BRIDGE Study
|
Park J.-W.; Chen M.; Colombo M.; Roberts L.R.; Schwartz M.; PEI-JER CHEN; Kudo M.; Johnson P.; Wagner S.; Orsini L.S.; Sherman M. |
| 臺大學術典藏 |
2021-07-03T03:33:57Z |
Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: Results of a randomized phase III trial
|
Cainap C.; Qin S.; Huang W.-T.; Chung I.J.; Pan H.; Cheng Y.; Kudo M.; Kang Y.-K.; PEI-JER CHEN; Toh H.-C.; Gorbunova V.; Eskens F.A.L.M.; Qian J.; McKee M.D.; Ricker J.L.; Carlson D.M.; El-Nowiem S. |
| 臺大學術典藏 |
2021-07-03T03:33:47Z |
Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
|
Omata M.; Cheng A.-L.; Kokudo N.; Kudo M.; Lee J.M.; Jia J.; Tateishi R.; Han K.-H.; Chawla Y.K.; Shiina S.; Jafri W.; Payawal D.A.; Ohki T.; Ogasawara S.; PEI-JER CHEN; Lesmana C.R.A.; Lesmana L.A.; Gani R.A.; Obi S.; Dokmeci A.K.; Sarin S.K. |
| 臺大學術典藏 |
2021-02-19T06:52:26Z |
Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies
|
Yen C.-J.;Kudo M.;Lim H.-Y.;Chih-Hung Hsu;Vogel A.;Brandi G.;Cheng R.;Nitu I.S.;Abada P.;Hsu Y.;Zhu A.X.;Kang Y.-K.; Yen C.-J.; Kudo M.; Lim H.-Y.; CHIH-HUNG HSU; Vogel A.; Brandi G.; Cheng R.; Nitu I.S.; Abada P.; Hsu Y.; Zhu A.X.; Kang Y.-K. |
| 臺大學術典藏 |
2021-02-19T06:52:25Z |
Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab
|
Zhu A.X.;Finn R.S.;Kang Y.-K.;Yen C.-J.;Galle P.R.;Llovet J.M.;Assenat E.;Brandi G.;Motomura K.;Ohno I.;Daniele B.;Vogel A.;Yamashita T.;Chih-Hung Hsu;Gerken G.;Bilbruck J.;Hsu Y.;Liang K.;Widau R.C.;Wang C.;Abada P.;Kudo M.; Zhu A.X.; Finn R.S.; Kang Y.-K.; Yen C.-J.; Galle P.R.; Llovet J.M.; Assenat E.; Brandi G.; Motomura K.; Ohno I.; Daniele B.; Vogel A.; Yamashita T.; CHIH-HUNG HSU; Gerken G.; Bilbruck J.; Hsu Y.; Liang K.; Widau R.C.; Wang C.; Abada P.; Kudo M. |
| 臺大學術典藏 |
2021-02-18T08:01:12Z |
The afsumb consensus statements and recommendations for the clinical practice of contrast-enhanced ultrasound using sonazoid
|
Lee J.Y.; Minami Y.; Choi B.I.; Lee W.J.; Chou Y.-H.; Jeong W.K.; Park M.-S.; Kudo N.; Lee M.W.; Kamata K.; Iijima H.; Kim S.Y.; Numata K.; Sugimoto K.; Maruyama H.; Sumino Y.; Ogawa C.; Kitano M.; Joo I.; Arita J.; JA-DER LIANG; Lin H.-M.; Nolsoe C.; Gilja O.H.; Kudo M. |
| 臺大學術典藏 |
2021-02-18T08:01:11Z |
The AFSUMB consensus statements and recommendations for the clinical practice of contrast-enhanced ultrasound using sonazoid
|
Lee J.Y.; Minami Y.; Choi B.I.; Lee W.J.; Chou Y.-H.; Jeong W.K.; Park M.-S.; Kudo N.; Lee M.W.; Kamata K.; Iijima H.; Kim S.Y.; Numata K.; Sugimoto K.; Maruyama H.; Sumino Y.; Ogawa C.; Kitano M.; Joo I.; Arita J.; JA-DER LIANG; Lin H.-M.; Nolsoe C.; Gilja O.H.; Kudo M. |
| 臺大學術典藏 |
2021-02-18T02:09:13Z |
Corrigendum to Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis
|
Yau T.;Chiun Hsu;Kim T.-Y.;Choo S.-P.;Kang Y.-K.;Hou M.-M.;Numata K.;Yeo W.;Chopra A.;Ikeda M.;Kuromatsu R.;Moriguchi M.;Chao Y.;Zhao H.;Anderson J.;Dela Cruz C.;Kudo M.; Yau T.; Chiun Hsu; Kim T.-Y.; Choo S.-P.; Kang Y.-K.; Hou M.-M.; Numata K.; Yeo W.; Chopra A.; Ikeda M.; Kuromatsu R.; Moriguchi M.; Chao Y.; Zhao H.; Anderson J.; Dela Cruz C.; Kudo M. |
| 臺大學術典藏 |
2021-02-18T02:09:12Z |
Efficacy and Safety of Nivolumab plus Ipilimumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib: The CheckMate 040 Randomized Clinical Trial
|
Yau T.;Kang Y.-K.;Kim T.-Y.;El-Khoueiry A.B.;Santoro A.;Sangro B.;Melero I.;Kudo M.;Hou M.-M.;Matilla A.;Tovoli F.;Knox J.J.;Ruth He A.;El-Rayes B.F.;Acosta-Rivera M.;Lim H.-Y.;Neely J.;Shen Y.;Wisniewski T.;Anderson J.;Chiun Hsu; Yau T.; Kang Y.-K.; Kim T.-Y.; El-Khoueiry A.B.; Santoro A.; Sangro B.; Melero I.; Kudo M.; Hou M.-M.; Matilla A.; Tovoli F.; Knox J.J.; Ruth He A.; El-Rayes B.F.; Acosta-Rivera M.; Lim H.-Y.; Neely J.; Shen Y.; Wisniewski T.; Anderson J.; Chiun Hsu |
| 臺大學術典藏 |
2021-02-18T02:09:11Z |
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
|
Cheng A.-L.;Chiun Hsu;Chan S.L.;Choo S.-P.;Kudo M.; Cheng A.-L.; Chiun Hsu; Chan S.L.; Choo S.-P.; Kudo M. |
| 國立成功大學 |
2021 |
Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2
|
Kudo, M.;Galle, P.R.;Brandi, G.;Kang, Y.-K.;Yen, C.-J.;Finn, R.S.;Llovet, J.M.;Assenat, E.;Merle, P.;Chan, S.L.;Palmer, D.H.;Ikeda, M.;Yamashita, T.;Vogel, A.;Huang, Y.-H.;Abada, P.B.;Yoshikawa, R.;Shinozaki, K.;Wang, C.;Widau, R.C.;Zhu, A.X. |
